Table 3.
Compounds Affecting TMR-FLT of cC0-C2, cC0-C2#P and fC1-C2
| Compounds | cC0-C2 |
cC0-C2#P |
fC1-C2 |
||
|---|---|---|---|---|---|
| FLT change | FLT change | cC0-C2/cC0-C2#P | FLT change | cC0-C2/fC1-C2 | |
| Erythromycin estolate | −14.1% | −2.4% | 5.9 | −2.1% | 6.7 |
| Clindamycin palmitate HCl | −12.7% | −10.2% | 1.2 | −1.2% | 10.6 |
| Scutellarin | −9.1% | −8.7% | 1.0 | −9.5% | 1.0 |
| Fidaxomicin | −5.2% | −0.5% | 10.4 | −4.3% | 1.2 |
| Fenticonazole nitrate | −4.7% | −6.0% | 0.8 | 0.4% | 11.8 |
| Bedaquiline fumarate | −4.5% | −6.5% | 0.7 | 6.7% | 0.7 |
| Fostamatinib (R788) | 2.3% | 0.7% | 3.3 | 0.4% | 5.8 |
| Chloroquine phosphate | 2.5% | 3.1% | 0.8 | 1.9% | 1.3 |
| Hederagenin | 2.5% | 3.6% | 0.7 | 2.3% | 1.1 |
| Enoxaparin sodium | 3.1% | 6.9% | 0.4 | 2.8% | 1.1 |
| Tocofersolan | 3.3% | 3.2% | 1.0 | 2.8% | 1.2 |
| Tamibarotene | 5.2% | 7.2% | 0.7 | 5.9% | 0.9 |
| Saikosaponin D | 5.4% | 6.3% | 0.9 | 4.2% | 1.3 |
| Verteporfin∗ | 5.5% | 6.8% | 0.8 | 2.5% | 2.2 |
| Troxerutin | 6.1% | 7.3% | 0.8 | 6.0% | 1.0 |
| α-Hederin | 6.7% | 7.1% | 0.9 | 6.7% | 1.0 |
| Cefsulodin sodium | 9.1% | 8.1% | 1.1 | 11.5% | 0.8 |
| Febuxostat | 9.6% | 12.1% | 0.8 | 14.6% | 0.7 |
| Erlotinib | 9.8% | 9.7% | 1.0 | 8.5% | 1.2 |
| Nilotinib hydrochloride | 10.1% | 14.1% | 0.7 | 15.6% | 0.6 |
| Ertapenem sodium | 10.2% | 8.0% | 1.3 | 12.2% | 0.8 |
| Triclocarban | 11.6% | 18.2% | 0.6 | 22.2% | 0.5 |
| Erlotinib HCl | 11.8% | 13.9% | 0.8 | 11.1% | 1.1 |
| Pneumocandin B0 | 12.4% | 13.2% | 0.9 | 11.4% | 1.1 |
| Paritaprevir (ABT-450) | 23.8% | 20.3% | 1.2 | 11.0% | 2.2 |
| Pranlukast | 30.7% | 50.1% | 0.6 | 50.3% | 0.6 |
| Anidulafungin | 32.1% | 43.3% | 0.7 | 53.0% | 0.6 |